Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234297 · ClinicalTrials.gov registry record · Phase 1
Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery
A Phase 1 study of Glioma, sponsored by Blaze Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT02234297 is a Phase 1 study of Glioma that has completed, run by Blaze Bioscience. The registered enrollment target is 17 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02234297, a Phase 1 study of Glioma, has completed, sponsored by Blaze Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. We hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as operate. This is a safety study to assess the safety of BLZ-100 in patients with gliomas undergoing surgery.
Conditions Studied
Interventions
- DRUG BLZ-100
Study Locations (2)
California
- Cedars-Sinai Medical Center - Los Angeles
Queensland
- NEWRO Foundation - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02234297
The ClinicalTrials.gov registry entry for NCT02234297 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (92% lower). The listed sponsor is Blaze Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which BLZ-100 is the first listed.
NCT02234297 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Queensland.
Frequently Asked Questions
What is clinical trial NCT02234297 about?
NCT02234297 is a clinical study titled "Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery". Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor...
What is the current status of trial NCT02234297?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-10. Estimated completion is 2016-03.
What conditions does trial NCT02234297 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT02234297?
The interventions under investigation include: BLZ-100 (DRUG).
Who is sponsoring clinical trial NCT02234297?
This trial is sponsored by Blaze Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02234297 being conducted?
This trial has 2 study locations across California, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.